Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy

Clinical trial NCT06161922 · COMPLETED

Trial details

NCT number: NCT06161922
Sponsor: Fudan University
Status: COMPLETED
Study type: OBSERVATIONAL

HER2-positive Breast Cancer

Start date: 2023-11-07
Primary completion: 2025-07-08
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.